Reducing Carbs Doesn’t Boost Insulin Response or Heart Health in Type 1 Diabetes
A research study looked at the impact of a 1-week low-carbohydrate diet on increasing insulin sensitivity and vascular function in type 1 diabetes.
IL-22 Links Inflammation, Diabetes, and Sitagliptin Therapy
A recent study conducted by the Mailman School of Public Health at Columbia University has discovered that adults with diabetes who exercise according to guidelines can lower their risk of premature death regardless of the number of hours spent sitting per day. This is the first study to demonstrate that regular exercise can reverse the risks of sitting for long periods, particularly in individuals with diabetes. The results of this study were published in the journal Diabetes Care.
Staying Active Offsets Health Risks of Prolonged Sitting in Diabetes Patients
A recent study conducted by the Mailman School of Public Health at Columbia University has discovered that adults with diabetes who exercise according to guidelines can lower their risk of premature death regardless of the number of hours spent sitting per day. This is the first study to demonstrate that regular exercise can reverse the risks of sitting for long periods, particularly in individuals with diabetes. The results of this study were published in the journal Diabetes Care.
MiRNAs and Nutritional Therapy for T2DM Remission in CHD: CORDIOPREV Findings
This study from the CORDIOPREV trial explored how small genetic molecules known as microRNAs (miRNAs) could assist doctors in selecting the most suitable diet for patients with both heart disease and Type 2 diabetes, potentially aiding in the reversal of their diabetes.
Platelet Health in Type 2 Diabetes: Exploring Immature Platelet Fraction and Other Markers
The study aims to explore how type 2 diabetes mellitus (T2DM) affects platelet function, specifically focusing on the immature platelet fraction (IPF) and other platelet indices. The research was conducted at Guru Teg Bahadur Hospital in New Delhi, India, and involved 230 participants, equally divided between T2DM patients and healthy controls.
Merilog Becomes First FDA-Approved Rapid-Acting Insulin Biosimilar for Diabetes Care
The U.S. Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj), a Novolog (insulin aspart) biosimilar, for the control of glycemia in adults and pediatric patients with diabetes mellitus. Merilog is the first FDA-approved rapid-acting insulin biosimilar and is available as a 3 mL prefilled pen and a 10 mL multiple-dose vial. Merilog reduces mealtime blood sugar surges, allowing for improved control of diabetes.
